UBS has downgraded XPeng shares to Sell, citing potential risks not reflected in the stock's current price after a 50% rally. Despite raising 2025 volume projections by 19% to 300,000 units, UBS's price target of $8.80 remains over 30% below the current market price, reflecting concerns over weak profit margins and high volatility. Other analysts have mixed views, with Goldman Sachs downgrading to Neutral but raising the price target to $12.50, while CMB International upgraded to Buy, highlighting cost reductions and new models.